SEC Form 10-K filed by Rein Therapeutics Inc.
$RNTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2025 | $10.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering
Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2
PRE 14A - Rein Therapeutics, Inc. (0001420565) (Filer)
10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)
SCHEDULE 13G - Rein Therapeutics, Inc. (0001420565) (Subject)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)